, Hong Kong
102 views
/Hong Kong Baptist University.

HKBU plans trial for ulcerative colitis remission drug in 2025

It will be randomised, double-blind, and placebo-controlled.

The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University plans to launch a Phase II clinical trial for its new drug, CDD-2103, in mainland China next year.

Designed for patients with ulcerative colitis showing symptoms of spleen deficiency and internal damp-heat accumulation, the Chinese formulation seeks to maintain remission, an area where existing treatments fall short.

The team's clinical study showed that patients who used the drug in a decoction format tolerated it well, with no reported adverse effects.

The trial, aimed at verifying the drug's safety and effectiveness in maintaining remission, will be randomised, double-blind, and placebo-controlled.

The CDD expects to complete larger-scale trials within the next five years. Once sufficient data is collected, the centre will apply for new drug approval from the National Medical Products Administration to bring the drug to market.

 

Join Hong Kong Business community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

HK leads in business confidence index in GBA
However, the current performance index for business activity dropped to 50.6 from 54.1.
Economy
EMSD rolls out Green Welfare NGOs scheme applications
First batch applications will open on 14 October, whilst second batch opens on 30 November.
Hang Seng indexes to include Alibaba-W
This move further enhances mainland Chinese investors' access to its shares.